STOCK TITAN

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has approved inducement grants for 34 new employees on July 1, 2022. The grants comprise a total of 138,000 restricted stock units, with 70,000 units awarded to the new chief commercial officer, Tracie Oliver. These grants are outside the company's stockholder-approved equity incentive plans and will vest over four years. Arrowhead focuses on developing RNA interference-based therapies to treat severe diseases by silencing problematic genes.

Positive
  • Inducement grants of 138,000 restricted stock units approved for 34 new employees.
  • Significant grant of 70,000 units to Tracie Oliver, indicating confidence in new leadership.
Negative
  • None.

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 1, 2022, the Compensation Committee of the Company’s Board of Directors approved “inducement” grants to 34 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 138,000 restricted stock units, including 70,000 restricted stock units granted to Tracie Oliver, the Company’s new chief commercial officer. The grants are outside the Company’s stockholder-approved equity incentive plans and vest annually over four years.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

Source: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.

Vince Anzalone, CFA

626-304-3400

ir@arrowheadpharma.com

Investors:

LifeSci Advisors, LLC

Brian Ritchie

212-915-2578

britchie@lifesciadvisors.com

www.lifesciadvisors.com

Media:

LifeSci Communications, LLC

Josephine Belluardo, Ph.D.

646-751-4361

jo@lifescicomms.com

www.lifescicommunications.com

Source: Arrowhead Pharmaceuticals, Inc.

FAQ

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades under the stock symbol ARWR.

When did Arrowhead Pharmaceuticals announce the inducement grants?

Arrowhead Pharmaceuticals announced the inducement grants on July 1, 2022.

How many restricted stock units were granted to new employees at Arrowhead Pharmaceuticals?

A total of 138,000 restricted stock units were granted to 34 new employees.

Who received the largest grant of restricted stock units at Arrowhead Pharmaceuticals?

Tracie Oliver, the new chief commercial officer, received 70,000 restricted stock units.

Are the inducement grants part of Arrowhead Pharmaceuticals' equity incentive plans?

No, the inducement grants are outside the company's stockholder-approved equity incentive plans.

Arrowhead Research Corporation

NASDAQ:ARWR

ARWR Rankings

ARWR Latest News

ARWR Stock Data

2.46B
118.89M
4.47%
79.71%
7.6%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PASADENA